Drug Trial Radar · NCT03523858
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
927
Actual
Start
May 28, 2018
Primary completion
Oct 22, 2026
Study completion Oct 22, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- May 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).
Conditions
- Progressive Multiple Sclerosis (PMS)
Interventions
OcrelizumabDrug
Ocrelizumab will be administered via intravenous (IV) infusion at an initial dose of two 300-mg infusions separated by 14 days (on Days 1 and 15), and then 600 mg at every subsequent dose every 24 weeks for the remainder of the study treatment period (approximately 192 weeks)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants with No Evidence of Progression (NEP)Time frame: From Baseline to Week 96, Week 96 to Week 192 and Baseline to Week 192
- Proportion of Participants with no evidence of progression and no active disease (NEPAD)Time frame: From Baseline to Week 96, Week 96 to Week 192 and Baseline to Week 192
Locations
120 sites in 24 countries. Site status is shown where the registry gives one.
MS Center of California
Laguna Hills, California
SC3 Research Group, Inc
Pasadena, California
University of California San Francisco
San Francisco, California
University of South Florida
Tampa, Florida
University of Chicago
Chicago, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Dragonfly Research, LLC
Wellesley, Massachusetts
Wayne State University School of Medicine
Detroit, Michigan
Washington University School of Medicine
St Louis, Missouri
The MS Center of Northeastern New York
Latham, New York
University of Cincinnati
Cincinnati, Ohio
Neurology Clinic PC
Cordova, Tennessee
Central Texas Neurology Consultants
Round Rock, Texas
Lone Star Neurology of San Antonio
San Antonio, Texas
Swedish Multiple Sclerosis Center
Seattle, Washington
University Clinical Center of the Republic of Srpska
Banja Luka, Bosnia and Herzegovina
University Hospital Mostar
Mostar, Bosnia and Herzegovina
Clinical Center University of Sarajevo
Sarajevo, Bosnia and Herzegovina
University Clinical Center Tuzla
Tuzla, Bosnia and Herzegovina
Instituto de Neurologia de Curitiba
Curitiba, Paraná, Brazil
Hospital Sao Lucas - PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital das Clínicas Faculdades Médicas de Ribeirão Preto
Ribeirão Preto, São Paulo, Brazil
Hospital das Clinicas - FMUSP_X
São Paulo, São Paulo, Brazil
Fraser Health Authority - Fraser Health Multiple Sclerosis
Burnaby, British Columbia, Canada
University of British Columbia Hospital
Vancouver, British Columbia, Canada
London Health Sciences Centre Uni Campus
London, Ontario, Canada
St. Michael'S Hospital
Toronto, Ontario, Canada
Recherche Sepmus Inc.
Greenfield Park, Quebec, Canada
Hospital Notre-Dame du Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada
Saskatoon City Hospital
Saskatoon, Saskatchewan, Canada
Organizacion Sanitas Internacional
Bogotá, Colombia
Fundacion Clinica Valle del Lili
Cali, Colombia
Hospital Clínica Biblica
San José, Costa Rica
Nemocnice Jihlava
Jihlava, Czechia
Fakultní Nemocnice Olomouc
Olomouc, Czechia
Fakultni nemocnice Ostrava
Ostrava-Poruba, Czechia
Vseobecna fakultni nemocnice v Praze
Prague, Czechia
Aarhus Universitetshospital
Aarhus N, Denmark
Rigshospitalet
Glostrup Municipality, Denmark
Hjerne- og nervesygdomme, Ambulatorium, Skleroseklinikken
Sønderborg, Denmark
Showing 40 of 120 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.